ENG

ENG简体中文日本語한국어

  • Zexiong WEN

    Equity Partner / Chengdu

  • Tel +86-28-6208-8013

    Email wenzexiong@zhonglun.com

  • Practices

    Chinese Mainland Capital Markets, Investment/M&A & Corporate Governance, Private Equity & Investment Funds

  • Industries

    Mining & Natural Resources, Pharmaceuticals & Life Sciences

CV

Zexiong WEN

Mr. Wen focuses on capital markets and has been practicing for over 20 years, especially on full-service legal advice to clients in complex legal matters, including restructuring, initial public offering, refinancing, merger and acquisition, reorganization and restructuring. The industries involved include medicine (including biological medicine), mining, energy, machinery and equipment, chemical, electric power, military, Internet and software, etc. His most representative case is Tianqi Lithium Corporation (002466) acquired the Australian Talison Lithium Pty Ltd in the year of 2014 and won China M&A Gold Wutong for innovative service.

Representative Matters

Representative cases on initial public offering as Issuer’s Legal Counsel:

  • Advised Sichuan Kelun Pharmaceutical Co., Ltd.(002242) on IPO Projects

  • Advised Houpu Clean Energy Group Co., Ltd. (300471) on IPO Projects

  • Advised Yibin Tianyuan Group Co., Ltd. (002386) on IPO Projects

  • Advised Sichuan Chengfei Integration Technology Corp (002190) on IPO Projects

  • Advised Chengdu Wintrue Holdings Co., Ltd. (002539) on IPO Projects


Representative cases on M&A, reorganization and restructuring:

  • Represented Tianqi Lithium Corporation (002466) since its listing on a series of major acquisitions, including the acquisitions of Australian Talison Lithium Pty Ltd. (2014), Galaxy Resources Ltd. (2015), Sociedad Quimica y Minera de Chile S.A.(2018), etc.

  • Represented Sichuan Kelun Pharmaceutical Co., Ltd.(002242) since its listing on a series of major acquisitions, including the acquisitions of Chengdu Qingshan LiKang Pharmaceutical Co. Ltd., SSY Group Ltd. (02005), Cisen Pharmaceutical Co., Ltd.(603367), etc.


Representative cases on refinancing as Issuer’s Legal Counsel:

  • Advised Sichuan Kelun Pharmaceutical Co., Ltd.(002242) on public issuance of convertible bonds.

  • Advised Tianqi Lithium Corporation (002466) on several onshore and offshore refinancings, including A Share Rights Issue, issuance of H shares, issuance of Note, etc.

  • Advised Emeishan Tourism Co., Ltd.(000888) on Non-public Issuance of Shares.

  • Advised New Hope Liuhe Co.,Ltd.(000876) on Non-public Issuance of Shares.

  • Advised Hebei Baoshuo Co., Ltd. (600155) on Non-public Issuance of Shares.

  • Advised Chengdu Wintrue Holdings Co., Ltd. (002539) on several public or Non-public Issuance.

  • Advised Chengdu Guibao Science & Technology Co., Ltd. (300019)  on Non-public Issuance of Shares.


Advised as standing legal counsel for more than ten listed companies, including Sichuan Kelun Pharmaceutical Co., Ltd.(002242), Chengdu Wintrue Holdings Co., Ltd. (002539), Sichuan Chengfei Integration Technology Corp.Ltd (002190), Tianqi Lithium Corporation (002466), Houpu Clean Energy Group Co., Ltd. (300471), etc.

Honors and Awards

For Individual

Excellent Lawyer of Chengdu, Chengdu Lawyers Association 2011-2014

For Deal

Best Innovative Service in M&A and Reorganization" award & 2015 First China M&A Golden Wutong Award, China M&A Cooperation Alliance and selected by China Securities Journal, Tianqi Lithium Corp (002466) overseas acquisition of Australian Talison Lithium Pty Ltd. project

Related

  • Bar Admissions/Professional Qualifications

    PRC Bar, 1999

  • Education

    LL.M., Sichuan University
    LL.B., China University of Political Science and Law

  • Professional Experience

    Associate & Partner, Zhong Lun Law Firm
    Associate, King & Wood Mallesons
    Associate, Sichuan Hengcheng Law Firm
    Associate, Sichuan Zhongchen Law Firm

  • Languages

    Chinese